Navigation Links
WorldHeart Enters into a Recapitalization Agreement and Receives Bridge Financing
Date:6/23/2008

OAKLAND, Calif., June 23 /PRNewswire-FirstCall/ -- (Nasdaq: WHRT) World Heart Corporation ("WorldHeart") today announced that it has entered into a Recapitalization Agreement dated June 20, 2008 among WorldHeart, its wholly- owned subsidiary, World Heart Inc. ("WHI"), Abiomed, Inc. ("Abiomed"), Venrock Partners V, L.P., Venrock Associates V, L.P. and Venrock Entrepreneurs Fund V, L.P. (collectively, "Venrock"), Special Situations Fund III QP LP, Special Situations Cayman Fund, L.P., Special Situations Private Equity Fund, L.P., Special Situations Life Sciences Fund, L.P. and Austin Marxe (collectively, "SSF"), pursuant to which:

(i) WorldHeart will issue approximately 300,000,000 common shares for an aggregate purchase price of no less than US$30,000,000 (the "Issuance"). At Closing, Venrock will invest an aggregate of approximately $10,000,000 and SSF will invest an aggregate of approximately $9,000,000 and other investors are in discussions to invest the remainder (such other investors, together with Venrock and SSF, the "Investors");

(ii) Contingent on and simultaneous with the closing of the Issuance, Abiomed has agreed to convert the full amount of principal and interest owed on the US$5,000,000 8% Secured Convertible Promissory Note (the "Note") issued to Abiomed by WorldHeart and WHI into 86,000,000 common shares of WorldHeart (the "Conversion"). The Note is currently secured by a security interest in all of the assets of WorldHeart and WHI. In connection with the Conversion, Abiomed has also agreed to terminate the warrant it holds to purchase 3,400,000 common shares of WorldHeart, and to forgive other amounts owed to Abiomed by WorldHeart; and

(iii) Venrock and SSF have agreed to provide WorldHeart with a bri
'/>"/>

SOURCE World Heart Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. WorldHeart Announces Delisting Appeal Received and Will be Considered at Hearing July 10, 2008
2. WorldHeart Reports an Event of Default Under the Note Issued to Abiomed, Resignation of One of Its Board of Directors, and Results of Shareholder Vote at Its Annual Shareholders Meeting
3. WorldHeart 10-KSB Audit Report Includes Going Concern Qualification
4. WorldHeart Schedules Teleconference
5. CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
6. Microchip Biotechnologies, Inc. Enters Into License Arrangement With GE Healthcare for Fundamental Microfluidic Patents
7. Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center
8. CyberKnife Radiosurgery Used to Treat Lung Tumors at 90 Percent of Centers Worldwide
9. Chromos enters into loan and lending arrangements
10. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
11. CSC Continues Support of Centers for Disease Control and Prevention Through New Task Order
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 AudioNotch is ... new therapy for the treatment of tinnitus. Patients listen ... frequency, and over a period of weeks to months, their ... Therapy in two forms: Notched Music and Notched White Noise. ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of strategic ... business, and media events in the United States ... associate Virginia Cox , JD, is returning to the firm,s ... Cox re-joins 3D after more than two years of service ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management software, today ... In this role, Michelle will work with current and potential ... development of iLab products. Her main goal will be to ... scientific community by offering the most advanced, user-friendly, and high-impact ...
(Date:1/14/2014)... January 13, 2014 Bob Hainsey, a ... than 20 years in the industry, has joined ... Hainsey will serve as the society’s Science and Technology ... join SPIE as our Technology Strategist, further strengthening the ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... BASINGSTOKE, England and PHILADELPHIA, Pennysylvania, March 3, Shire ... biopharmaceutical company, notes that Renovo Group plc, (LSE:,RNVO) ... latest Phase 2,studies of JUVISTA(R) (human recombinant TGFbeta3) ... (RN1001-319-1010)., Renovo’s press release can be found ...
... and MONTREAL, March 3 /PRNewswire-FirstCall/ - AEterna,Zentaris Inc. ... company,focused on endocrine therapy and oncology, and Paladin ... company, announced today,that they have entered into a ... rights related to the manufacture, production, distribution,marketing, sale ...
... Feb. 29 Wyeth Pharmaceuticals,a division of Wyeth ... U.S. Food and,Drug Administration (FDA) has approved PRISTIQ(TM) ... treat adult patients with major depressive disorder (MDD). ... in the second,quarter of 2008., "We are ...
Cached Biology Technology:Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3) 2Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3) 3AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights 2AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights 3FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 2FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 3FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 4FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 5FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 6FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 7FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 8FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 9
(Date:4/20/2014)... gene expression analysis growing in importance for both ... Mellon University and the University of Maryland have ... up estimates of gene activity from RNA sequencing ... after the famously speedy fish, estimates of gene ... completed in a few minutes, with accuracy that ...
(Date:4/20/2014)... newborn baby a gift of germsgerms that help ... used to fend off infection, may paradoxically interrupt ... babies more susceptible to dangerous pathogens. , ... The Children,s Hospital of Philadelphia (CHOP) sheds light ... microbes play a crucial role in fostering the ...
(Date:4/20/2014)... crop residue to make ethanol and other biofuels reduces ... gasoline, according to a study published today in the ... by a University of Nebraska-Lincoln team of researchers cast ... meet federal mandates to ramp up ethanol production and ... stalks, leaves and cobs in cornfields after harvest -- ...
Breaking Biology News(10 mins):Computational method dramatically speeds up estimates of gene expression 2Study of gut microbes, antibiotics: Clues to improving immunity in premature infants 2Study casts doubt on climate benefit of biofuels from corn residue 2Study casts doubt on climate benefit of biofuels from corn residue 3
... called CD14 binds to substances liberated from the bacteria ... published in the Journal of Biological Chemistry, scientists in ... and showed how it is perfectly suited to bind ... the "Paper of the Week" in the March 25 ...
... number of genes we have in our genome—more than ... genetic truth has often been obscured. The expression of ... host of non-coding sequences, which bind transcription factors and ... coding sequences, whose signatures are easy to spot, the ...
... and MYC cooperate with each other to promote pediatric ... finding, from investigators at St. Jude Children's Research Hospital, ... Biology (MCB). , B-cell lymphoma is a cancer in ... crowd out other blood cells. The St. Jude researchers ...
Cached Biology News:Scientists solve structure of key protein in innate immune response 2Unexpressed But Indispensable -- The DNA Sequences That Control Development 2TEL2 gene cooperates with MYC gene to provoke B-cell lymphomas 2TEL2 gene cooperates with MYC gene to provoke B-cell lymphomas 3
...
Contains L-glutamine...
...
... ZMD.358. Immunogen: Synthetic peptide ... of human mouse and rat ... human and mouse LRP5 proteins. ... controls: mouse LRP5-pSEC-tag-transfected 293T cells ...
Biology Products: